The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma.

Solmaz, Serife; Uzun, Ozcan; Sevindik, Omur Gokmen; Demirkan, Fatih; Ozcan, Mehmet Ali; Ozsan, Guner Hayri; Alacacıoglu, Inci

Introduction: In multiple myeloma cases, a variety of prognostic parameters have been identified, which contain the Durie‐Salmon classification and the international staging system (ISS) that takes the serum ß2 microglobulin and albumin levels, platelet‐to‐lymphocyte ratio (PLR), neutrophil‐to‐lymphocyte ratio (NLR), and monocyte‐to‐lymphocyte ratio (MLR). This study investigates the effect of haemoglobin, albumin, lymphocyte and platelet (HALP) score which is a marker of inflammation status and nutrition, at the time of diagnosis for the patients with multiple myeloma on prognosis. Methods: A total of 200 multiple myeloma patients with HALP scores calculated from serum haemoglobin, albumin, lymphocyte count and platelet levels at the time of diagnosis were retrospectively examined. The effect of HALP score on overall survival (OS) and progression‐free survival and its relationship between the previously evaluated prognostic parameters were investigated. Results: The optimal cut‐off value with the ROC curves for the HALP score was 28.8. The patients were divided into two groups according to the optimal value of the HALP score (low‐score group: HALP ≤28.8 [n: 134] and high‐score group HALP >28.8 [n: 66]). In the group with the high HALP score, the OS was statistically longer than the low HALP score group (84 months and 53 months; p = 0.0001). In addition, when the effects of NLR, PLR, HALP score and ISS stage on OS were examined by multivariate analysis, all these markers were found to be statistically significant predictors. Conclusions: HALP score may be a valuable prognostic marker for patients with multiple myeloma.

HEMOGLOBINS; PREDICTIVE tests; BLOOD platelets; INFLAMMATION; MULTIVARIATE analysis; RETROSPECTIVE studies; ACQUISITION of data; SERUM albumin; LYMPHOCYTES; MEDICAL records; SURVIVAL analysis (Biometry); MULTIPLE myeloma; TUMOR markers; PROGRESSION-free survival; RECEIVER operating characteristic curves; NUTRITIONAL status

International Journal of Laboratory Hematology, 2023, Vol 45, Issue 1, p13

1751-5521

Academic Journal

10.1111/ijlh.13958